

23 April 2025

**Argent BioPharma Ltd.**  
(Argent BioPharma or the Company)

**Notice Under Section 708A(5) of the Corporations Act 2001 (the Act)**

This notice is given by Argent BioPharma Limited (ASX: RGT) in relation to the issue of 12,910,884 fully paid ordinary shares (**Shares**) as detailed in the Appendix 2A's announced today.

The Corporations Act 2001 (Cth) (**Act**) restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, the Shares detailed in the Appendix 2A's announced on 23 April 2025 will fall within the exemption in section 708A(5) of the Act. Pursuant to section 708A(5)(e) of the Act, the Company gives notice that:

- a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- b) as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and sections 674 and 674A of the Act; and
- c) as at the date of this notice there is no information:
  - 1) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules; and
  - 2) that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of:
    - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - ii. the rights and liabilities attaching to the Shares.

**-ENDS-**

Authorised for release by the board of directors, for further information please contact:

**Argent BioPharma**  
Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**  
Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**About Argent BioPharma**

Argent BioPharma Limited (ASX: RGT) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology and advanced nanomedicine. By leveraging the Neuro-Immune Modulatory (NIM) System, Argent BioPharma's robust pipeline—including CannEpi®, CogniCann®, and CimetrA®—targets CNS disorders and immune-related conditions. With a commitment to science-driven innovation, Argent BioPharma is shaping the future of cannabinoid-based therapeutics and neuroimmune modulation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma  
Twitter: @ArgentBioPharma  
Facebook: Argent BioPharma